• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Hollis-Eden Pharmaceuticals Grants Extension of Offer to Department of Health and Human Services for Acute Radiation Syndrome Candidate

Posted on: Wednesday, 27 September 2006, 09:01 CDT

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced today that it

has granted a request from the Department of Health and Human Services

(HHS) that the Company extend through November 30, 2006 its offer

submitted under Request for Proposal (RFP) No. DHHS-ORDC-DDA-05-12

entitled "Medical Countermeasures to Mitigate

or Treat Neutropenia Alone or in Combination with Co-Morbidities

Associated with Acute Radiation Syndrome (ARS)."

While HHS has not provided Hollis-Eden with a new estimated contract

award date, based on this extension an award could be made under this

RFP at any time prior to the end of November 2006. As previously

announced, Hollis-Eden was informed by HHS in June that the Company "is

within the competitive range for discussion and further evaluation"

on a potential procurement of its lead drug candidate, NEUMUNE™

(HE2100), under this RFP. Since that time, Hollis-Eden has been in

ongoing discussions with HHS with respect to this potential procurement.

About Hollis-Eden

Hollis-Eden Pharmaceuticals, Inc. is developing a proprietary new class

of small molecule compounds that are metabolites or synthetic analogs of

adrenal steroid hormones. These compounds, designed to restore the

biological activity of cellular signaling pathways disrupted by disease

and aging, have been demonstrated in humans to possess several

properties with potential therapeutic benefit --

they regulate innate and adaptive immunity, reduce nonproductive

inflammation and stimulate cell proliferation. The Company's

lead product candidate, NEUMUNE™ (HE2100), is

entering late-stage development for the treatment of Acute Radiation

Syndrome (ARS), a life-threatening condition resulting from exposure to

high levels of radiation following a nuclear or radiological incident,

and is being explored for use in combating healthcare-associated

infections. Hollis-Eden also is profiling optimized second-generation

compounds for potential clinical development in a broad spectrum of

therapeutic categories including hematology, metabolic disorders,

autoimmune disorders, pulmonary diseases, oncology and infectious

diseases. For more information on Hollis-Eden, visit the Company's

website at www.holliseden.com.

This press release contains forward-looking statements within the

meaning of the federal securities laws concerning, among other things,

the potential and prospects of the Company's drug discovery program and

its drug candidates. Any statements included in this press release that

are not a description of historical facts are forward-looking statements

that involve risks, uncertainties, assumptions and other factors which,

if they do not materialize or prove correct, could cause the Company's

actual results to differ materially from historical results or those

expressed or implied by such forward-looking statements. Such statements

are subject to certain risks and uncertainties inherent in the Company's

business, including, but not limited to: the ability to complete

preclinical and clinical trials successfully and within specified

timelines, if at all; the ability to obtain regulatory approval for

NEUMUNE under the U.S. Food and Drug Administration Animal Efficacy

Rule, even if shown to be effective in preclinical studies; the ability

to receive any stockpiling orders for NEUMUNE from the U.S. federal,

state and foreign governments or agencies, even if approved by

regulatory authorities; the Company's future capital needs; the

Company's ability to obtain additional funding; the ability of the

Company to protect its intellectual property rights and to not infringe

the intellectual property rights of others; the development of

competitive products by other companies; and other risks detailed from

time to time in the Company's filings with the Securities and Exchange

Commission. Existing and prospective investors are cautioned not

to place undue reliance on these forward-looking statements, which speak

only as of the date of this press release. Except as required by

law, the Company undertakes no obligation to update or revise the

information contained in this press release as a result of new

information, future events or circumstances arising after the date of

this press release.

Source: Business Wire

More News in this Category